郑顺文,戴锦杰,施鸿毓,秦牧,陈晖,吴卫华,刘旭,何奔,仇兴标

• 1:上海交通大学附属胸科医院心内科

摘要(Abstract)：

目的评估经皮室间隔化学消融术(PTSMA)在老年药物难治性梗阻性肥厚型心肌病患者中的有效性和安全性。方法连续收录上海交通大学附属胸科医院2001年4月至2019年1月行PTSMA治疗的梗阻性肥厚型心肌病患者,按照年龄分成青年组(年龄<55岁)和老年组(年龄≥55岁)。通过查阅病历记录患者的一般资料、临床病史、手术情况及住院期间并发症发生情况,以及通过电话或门诊随访所记录患者的生命状态、临床表现和心功能情况,应用Kaplan-Meier法分析两组生存曲线。结果共111例患者纳入本研究,中位年龄为56.0(15.0,82.0)岁,女性共42例(37.8%),其中青年组中位年龄43.5(15.0,54.0)岁,老年组中位年龄为63.0(55.0,82.0)岁。总体消融成功率为68.5%,青年组、老年组分别为66.7%、70.0%。术中无水酒精中位注射量为2.0(1.0,5.0)ml,青年组和老年组分别为2.1(1.0,5.0)ml和2.0(1.0,5.0)ml,两组比较差异无统计学意义(P=0.728)。房室传导阻滞、室性心律失常、低血压为手术常见并发症,2例患者(均≥55岁)因持续高度房室传导阻滞需植入永久起搏器,1例患者(66岁)因术后心室颤动、心原性休克经抢救无效死亡。老年组患者围术期主要不良心血管事件(包括心原性死亡,高度房室传导阻滞需植入永久起搏器,由于心室颤动或室性心动过速引起的心搏骤停复苏等)发生率较青年组高(P=0.060)。111例患者除外1例围术期死亡,对其余110例患者进行了长期随访,随访时间为3～212(35.5±48.5)个月,随访率为86.4%(95/110),全因死亡11例,总死亡率为10.0%(11/110),除外1例因肺部感染死亡,其余10例为肥厚型心肌病相关死亡,包括6例心原性猝死,3例因心房颤动、急性脑梗死致死,1例心力衰竭致死。梗阻性肥厚型心肌病患者PTSMA后1年、5年和10年的总生存率分别为96.9%、93.4%和81.1%。青年组和老年组1年、5年、10年总生存率分别97.7%、97.7%、91.6%和96.2%、89.7%、66.4%(P=0.068)。结论老年梗阻性肥厚型心肌病患者PTSMA的效果与青年患者相当,但手术相关的主要不良心血管事件风险可能增加,术后长期总生存率略低于青年组患者。

关键词(KeyWords)： 梗阻性肥厚型心肌病;经皮室间隔化学消融术;有效性;安全性;老年

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81770324)

作者(Author): 郑顺文,戴锦杰,施鸿毓,秦牧,陈晖,吴卫华,刘旭,何奔,仇兴标

参考文献(References)：

• [1] Veselka J, Krej?íJ, Toma?ov P, et al. Survival of patients≤50years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol,2014,30(6):634-638.
• [2] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Thorac Cardiovasc Surg,2011,142(6):e153-e203.
• [3] SEC Working Group for the 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy,expert reviewers for the ESC 2014 guidelines on the diagnosis and management of hypertrophic cardiomyopathy,SEC Clinical Practice Guidelines Committee. Comments on the 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. A critical view from the perspective of Spanish cardiology. Rev Esp Cardiol(Engl Ed),2015,68(1):4-9.
• [4] Singh K, Qutub M, Carson K, et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv,2016,88(1):107-115.
• [5]石蕴琦，李占全.梗阻性肥厚型心肌病介入治疗与手术治疗的比较.中国介入心脏病学杂志，2015, 23(5):291-293.
• [6] Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy:role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol, 2015,66(11):1307-1308.
• [7] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet,1995,346(8969):211-224.
• [8] Batzner A, Pfeiff er B, Neugebauer A, et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol,2018,72(24):3087-3094.
• [9] Liebregts M, Faber L, Jensen MK, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv,2017,10(11):1134-1143.
• [10] Rigopoulos AG, Seggewiss H. Twenty years of alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Curr Cardiol Rev,2016,12(4):285-296.
• [11] Liebregts M, Steggerda RC, Vriesendorp PA, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv,2016,9(5):463-469.
• [12] Veselka J, Krej?íJ, Toma?ov P, et al. Long-term survival af ter alcohol septal ablation f or hypertrophic obstructive cardiomyopathy:a comparison with general population. Eur Heart J,2014,35(30):2040-2045.
• [13] Cheddadi L, Lairez O, Lhermusier T, et al. E?cacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy. Clin Interv Aging,2017,12:467-473.
• [14] Liu Q, Li D, Berger AE, et al. Survival and prognostic factors in hypertrophic cardiomyopathy:a meta-analysis. Sci Rep,2017,7(1):11957.
• [15]刘蓉，乔树宾，胡奉环，等.肥厚型心肌病化学消融术疗效与冠状动脉特点的相关性研究.中国介入心脏病学杂志，2016,24(6):311-315.
• [16] Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy:results from the Euro-ASA registry. Eur Heart J,2016,37(19):1517-1523.